156 related articles for article (PubMed ID: 37605478)
1. Treating rosacea with botulism toxin: Protocol for a systematic review and meta-analysis.
He G; Yang Q; Wu J; Huang Y; Zheng H; Cheng H
J Cosmet Dermatol; 2024 Jan; 23(1):44-61. PubMed ID: 37605478
[TBL] [Abstract][Full Text] [Related]
2. Pulsed dye laser followed by intradermal botulinum toxin type-A in the treatment of rosacea-associated erythema and flushing.
Al-Niaimi F; Glagoleva E; Araviiskaia E
Dermatol Ther; 2020 Nov; 33(6):e13976. PubMed ID: 32633449
[TBL] [Abstract][Full Text] [Related]
3. Botulinum toxin for the treatment of refractory erythema and flushing of rosacea.
Park KY; Hyun MY; Jeong SY; Kim BJ; Kim MN; Hong CK
Dermatology; 2015; 230(4):299-301. PubMed ID: 25765295
[TBL] [Abstract][Full Text] [Related]
4. The toxic edge-A novel treatment for refractory erythema and flushing of rosacea.
Friedman O; Koren A; Niv R; Mehrabi JN; Artzi O
Lasers Surg Med; 2019 Apr; 51(4):325-331. PubMed ID: 30311683
[TBL] [Abstract][Full Text] [Related]
5. A randomized, controlled, split-face study of botulinum toxin and broadband light for the treatment of erythematotelangiectatic rosacea.
Tong Y; Luo W; Gao Y; Liu L; Tang Q; Wa Q
Dermatol Ther; 2022 May; 35(5):e15395. PubMed ID: 35187781
[TBL] [Abstract][Full Text] [Related]
6. A Pilot Study to Evaluate the Efficacy and Safety of Treatment with Botulinum Toxin in Patients with Recalcitrant and Persistent Erythematotelangiectatic Rosacea.
Park KY; Kwon HJ; Kim JM; Jeong GJ; Kim BJ; Seo SJ; Kim MN
Ann Dermatol; 2018 Dec; 30(6):688-693. PubMed ID: 33911508
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Skin Physiology Change and Safety After Intradermal Injections With Botulinum Toxin: A Randomized, Double-Blind, Placebo-Controlled, Split-Face Pilot Study in Rosacea Patients With Facial Erythema.
Kim MJ; Kim JH; Cheon HI; Hur MS; Han SH; Lee YW; Choe YB; Ahn KJ
Dermatol Surg; 2019 Sep; 45(9):1155-1162. PubMed ID: 30730346
[TBL] [Abstract][Full Text] [Related]
8. Botulinum Toxin A Alleviates Persistent Erythema and Flushing in Patients with Erythema Telangiectasia Rosacea.
Yang R; Liu C; Liu W; Luo J; Cheng S; Mu X
Dermatol Ther (Heidelb); 2022 Oct; 12(10):2285-2294. PubMed ID: 35925473
[TBL] [Abstract][Full Text] [Related]
9. Use of Botulinum Toxin in Treating Rosacea: A Systematic Review.
Zhang H; Tang K; Wang Y; Fang R; Sun Q
Clin Cosmet Investig Dermatol; 2021; 14():407-417. PubMed ID: 33958886
[TBL] [Abstract][Full Text] [Related]
10. Facial flushing and erythema of rosacea improved by carvedilol.
Seo BH; Kim DH; Suh HS; Choi YS
Dermatol Ther; 2020 Nov; 33(6):e14520. PubMed ID: 33174351
[TBL] [Abstract][Full Text] [Related]
11. Botulinum toxin blocks mast cells and prevents rosacea like inflammation.
Choi JE; Werbel T; Wang Z; Wu CC; Yaksh TL; Di Nardo A
J Dermatol Sci; 2019 Jan; 93(1):58-64. PubMed ID: 30658871
[TBL] [Abstract][Full Text] [Related]
12. Botulinum Toxin: An Effective Treatment for Flushing and Persistent Erythema in Rosacea.
Luque A; Rojas AP; Ortiz-Florez A; Perez-Bernal J
J Clin Aesthet Dermatol; 2021 Mar; 14(3):42-45. PubMed ID: 33841616
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of botulinum toxin for rosacea with positive impact on quality of life and self-esteem.
Takahashi KH; Utiyama TO; Bagatin E; Picosse FR; Almeida FA
Int J Dermatol; 2024 May; 63(5):590-596. PubMed ID: 38246911
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Botulinum Toxin in the Treatment of Cutaneous Flushing: A Systematic Review and Meta-Analysis.
Vincent N; Ravipati A; Reynolds JM; Kaufman J
Dermatol Surg; 2024 Apr; 50(4):354-359. PubMed ID: 38232350
[TBL] [Abstract][Full Text] [Related]
15. The Efficacy and Safety of Botulinum Toxin A for the Treatment of Rosacea: A Systematic Review.
Alsaati AA; Alsaadoun D; Kinkar LI; Alkhamis RS; Ahmed WA; Almathami AH
Cureus; 2023 Dec; 15(12):e51304. PubMed ID: 38288198
[TBL] [Abstract][Full Text] [Related]
16. A new treatment regimen for rosacea: onabotulinumtoxinA.
Dayan SH; Pritzker RN; Arkins JP
J Drugs Dermatol; 2012 Dec; 11(12):e76-9. PubMed ID: 23377526
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin type B for cervical dystonia.
Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
Cochrane Database Syst Rev; 2005 Jan; (1):CD004315. PubMed ID: 15674941
[TBL] [Abstract][Full Text] [Related]
18. Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea.
Bloom BS; Payongayong L; Mourin A; Goldberg DJ
Dermatol Surg; 2015 Jan; 41 Suppl 1():S9-16. PubMed ID: 25548852
[TBL] [Abstract][Full Text] [Related]
19. Topical Oxymetazoline Cream 1.0% for Persistent Facial Erythema Associated With Rosacea: Pooled Analysis of the Two Phase 3, 29-Day, Randomized, Controlled REVEAL Trials.
Stein-Gold L; Kircik L; Draelos ZD; Werschler P; DuBois J; Lain E; Baumann L; Goldberg D; Kaufman J; Tanghetti E; Ahluwalia G; Alvandi N; Weng E; Berk D
J Drugs Dermatol; 2018 Nov; 17(11):1201-1208. PubMed ID: 30500142
[TBL] [Abstract][Full Text] [Related]
20. Use of beta-blockers for rosacea-associated facial erythema and flushing: A systematic review and update on proposed mode of action.
Logger JGM; Olydam JI; Driessen RJB
J Am Acad Dermatol; 2020 Oct; 83(4):1088-1097. PubMed ID: 32360760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
